Related Experiment Video
Updated: Feb 20, 2026

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization
Published on: October 3, 2025
TwoPhaseInd: an R package for estimating gene-treatment interactions and discovering predictive markers in randomized
1Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Abstract:
In randomized clinical trials, identifying baseline genetic or genomic markers for predicting subgroup treatment effects is of rising interest. Outcome-dependent sampling is often employed for measuring markers. The R package TwoPhaseInd implements a number of efficient statistical methods we developed for estimating subgroup treatment effects and gene-treatment interactions, exploiting the gene-treatment independence dictated by randomization, including the case-only estimator, the maximum estimated likelihood estimator and the semiparametric maximum likelihood estimator for parameters in a logistic model. For rare failure events subject to censoring, we have proposed efficient augmented case-only designs, a variation of the case-cohort design, to estimate genetic associations and subgroup treatment effects in a Cox regression model. The R package is computationally scalable to genome-wide studies, as illustrated by an example from Women's Health Initiative.
Availability And Implementation:
The R package TwoPhaseInd is available from http://cran.r-project.org/web/packages CONTACT: jdai@fredhutch.org.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs
Statistical Software for Data Analysis and Clinical Trials
Comparing the Survival Analysis of Two or More Groups
Clinical Trials
There are four phases in a clinical trial. A phase one...

